DXCM241018C65000
- 4.80
- +2.10+77.78%
DexCom Newsroom
DexCom Is Maintained at Outperform by RBC Capital
DexCom Analyst Ratings
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $120
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $89
Piper Sandler Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80
Oppenheimer Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $115
Wells Fargo Remains a Buy on Dexcom (DXCM)
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80
Analysts' Top Healthcare Picks: Dexcom (DXCM), Ascendis Pharma (ASND)
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80
Wells Fargo Releases a Buy Rating on Dexcom (DXCM)
Dexcom's Stelo Sees Strong Market Adoption: Justifying a Buy Rating
Morgan Stanley Maintains DexCom(DXCM.US) With Hold Rating, Cuts Target Price to $75
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $89
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $80 to $120
Dexcom's Strategic Market Expansion With Stelo CGM Launch Prompts Buy Rating
Barclays Keeps Their Hold Rating on Dexcom (DXCM)
DexCom Price Target Maintained With a $90.00/Share by Piper Sandler